Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Platzbecker, U

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. [electronic resource] - Leukemia Mar 2012 - 381-9 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1476-5551

10.1038/leu.2011.234 doi


Adult
Aged
Antimetabolites, Antineoplastic--adverse effects
Azacitidine--adverse effects
Chimerism
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Neoplasm, Residual--therapy
Recurrence
Time Factors
Transplantation, Homologous
Treatment Outcome
Young Adult